Why has immune “checkpoint” therapy failed in most clinical trials?
Sign Up to like & getrecommendations! Published in 2025 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2025-012457
Abstract: Cancer immunotherapy targeting the PD-1/PD-L1 pathway has demonstrated efficacy across a range of common solid tumors and some hematopoietic malignancies. Despite these groundbreaking successes, the clinical development of other ‘checkpoint inhibitors’ targeting molecules like TIM-3,… read more here.
Keywords: therapy failed; therapy; immune checkpoint; failed clinical ... See more keywords